Examination of improvement of endothelial function in diabetic patients with hypertension - FMD change in diabetic subjects

Saitama Medical Center, Saitama Medical University Department of endocrinology and dibaetes0 个研究点目标入组 20 人开始时间: 2010年6月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Subjects who have one or more of the below cases will be excluded. 1) Hypertensive emergency, or under non-oral anti-hypertensive medication 2) Nephritic syndrome (urine protein more than 3.5 g/day, or serum albumin is less than or equal to 3.0 g/dL 3) Subjects who take steroid or immunosuppressor, or ARB other than olmesartan, Ca-blocker other than azelnidipin, anti-fungal agents, HIV protease inhibitor, will be excluded. Subjects who take NSAIDs for more than or equal to 2 weeks will be excluded. 4) Previous history of sever adverse events with Ca-blocker, or ARB or ACE. 5) Subjects experienced brain stroke during six months before taking experimental medication will be excluded. 6) Sever congestive heart failure (NYHA class III or more), sever arrhythmia. Subjects experienced myocardial infarction, or PCT intervention during six months before taking experimental medical will be excluded. 7) Type 1 diabetes mellitus. HbA1C (JDS) more than or equal to 9.0%. Diabetic ketoacidosis 8) Liver dysfunction with increased AST or ALT which are more than 5 times than the upper limit of the standard value. 9) Subjects with malignant tumor 10) Pregnant, or expecting to be pregnant 11) Other problems which investigator (physician) felt inappropriate

发起方

Saitama Medical Center, Saitama Medical University Department of endocrinology and dibaetes